Technical Analysis for MGTX - MeiraGTx Holdings plc

Grade Last Price % Change Price Change
grade B 12.79 0.31% 0.04
MGTX closed up 0.31 percent on Friday, February 15, 2019, on 1.16 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Up
See historical MGTX trend table...

Date Alert Name Type % Chg
Feb 15 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Feb 15 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Feb 15 NR7 Range Contraction 0.00%
Feb 15 Earnings Movers Other 0.00%
Feb 15 Inside Day Range Contraction 0.00%
Feb 15 Wide Bands Range Expansion 0.00%
Feb 15 Overbought Stochastic Strength 0.00%
Feb 15 Up 3 Days in a Row Strength 0.00%
Feb 14 1,2,3 Pullback Bullish Bullish Swing Setup 0.31%
Feb 14 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.31%

Older signals for MGTX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:

Profile
  • Earnings date: 2019-02-14
MeiraGTx Holdings PLC is a clinical stage gene therapy company. Its pipeline products include AAV-CNGB3, AAV-CNGA3. AAV-UPF1, West AMD, Dry AMD, and others. Geographically, the company generates a majority of its revenue from the United Kingdom.
Technology California Gene Therapy Macular Degeneration Gene Delivery Adeno Associated Virus AAV Advanced Micro Devices Pipeline Products
Is MGTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Feb 15 FDA finalizes guidance for expedited review of cell and gene therapy applications
Feb 11 MeiraGTx (MGTX) Presents At BIO CEO & Investor Conference - Slideshow
Feb 7 Sangamo selloff weighs on gene therapy developers
Feb 5 MeiraGTx to Present at the BIO CEO & Investor Conference
Jan 31 Healthcare tops midday movers
Jan 31 48 Stocks Moving In Thursday's Mid-Day Session
Jan 31 Fortress Biotech leads healthcare gainers; AVEO Pharmaceuticals and Innoviva among losers
Jan 31 MeiraGTx teams up with Janssen to develop gene therapies for inherited retinal disorders
Jan 31 MeiraGTx Enters into Strategic Collaboration with Janssen to Develop and Commercialize Gene Therapy Treatments for Inherited Retinal Diseases
Jan 31 Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases
See more MGTX news...
Indicators
Indicator Value
52 Week High 15.49
52 Week Low 7.98
Average Volume 90,477
200-Day Moving Average 0.0
50-Day Moving Average 11.0928
20-Day Moving Average 11.398
10-Day Moving Average 12.501
Average True Range 0.8065
ADX 38.2
+DI 22.9877
-DI 8.9988
Chandelier Exit (Long, 3 ATRs ) 10.6805
Chandelier Exit (Short, 3 ATRs ) 11.5195
Upper Bollinger Band 14.0706
Lower Bollinger Band 8.7254
Percent B (%b) 0.76
BandWidth 46.895947
MACD Line 0.5647
MACD Signal Line 0.4001
MACD Histogram 0.1646
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.41
Resistance 3 (R3) 13.34 13.07 13.30
Resistance 2 (R2) 13.07 12.91 13.10 13.27
Resistance 1 (R1) 12.93 12.82 13.00 13.00 13.23
Pivot Point 12.66 12.66 12.70 12.69 12.66
Support 1 (S1) 12.52 12.50 12.59 12.59 12.35
Support 2 (S2) 12.25 12.41 12.28 12.31
Support 3 (S3) 12.11 12.25 12.28
Support 4 (S4) 12.18